Want to see DNTH full AI Analyst Report?
Total Valuation
Dianthus Therapeutics has a market cap or net worth of $4.93B. The enterprise value is $2.79B.
Market Cap$4.93B
Enterprise Value$2.79B
Share Statistics
Dianthus Therapeutics has 54,666,233 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,666,233
Owned by Insiders0.13%
Owned by Institutions55.84%
Financial Efficiency
Dianthus Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -35.55%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-35.55%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee22.13K
Profits Per Employee-1.76M
Employee Count92
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dianthus Therapeutics is ―. Dianthus Therapeutics’s PEG ratio is -0.15.
PE Ratio―
PS Ratio764.98
PB Ratio3.16
Price to Fair Value3.16
Price to FCF-12.05
Price to Operating Cash Flow-33.26
PEG Ratio-0.15
Income Statement
In the last 12 months, Dianthus Therapeutics had revenue of 2.04M and earned -162.34M in profits. Earnings per share was -4.20.
Revenue2.04M
Gross Profit2.04M
Operating Income-177.93M
Pretax Income-162.34M
Net Income-162.34M
EBITDA-161.91M
Earnings Per Share (EPS)-4.20
Cash Flow
In the last 12 months, operating cash flow was -130.29M and capital expenditures -199.00K, giving a free cash flow of -130.49M billion.
Operating Cash Flow-130.29M
Free Cash Flow-130.49M
Free Cash Flow per Share-2.39
Dividends & Yields
Dianthus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.98
52-Week Price Change390.81%
50-Day Moving Average86.71
200-Day Moving Average59.86
Relative Strength Index (RSI)53.83
Average Volume (3m)1.00M
Important Dates
Dianthus Therapeutics upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Dianthus Therapeutics as a current ratio of 13.32, with Debt / Equity ratio of 0.11%
Current Ratio13.32
Quick Ratio13.32
Debt to Market Cap<0.01
Net Debt to EBITDA0.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Dianthus Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Dianthus Therapeutics EV to EBITDA ratio is -9.31, with an EV/FCF ratio of -11.66.
EV to Sales740.57
EV to EBITDA-9.31
EV to Free Cash Flow-11.66
EV to Operating Cash Flow-11.68
Balance Sheet
Dianthus Therapeutics has $1.11B in cash and marketable securities with $1.36M in debt, giving a net cash position of $1.11B billion.
Cash & Marketable Securities$1.11B
Total Debt$1.36M
Net Cash$1.11B
Net Cash Per Share$20.30
Tangible Book Value Per Share$13.05
Margins
Gross margin is 94.31%, with operating margin of -8739.34%, and net profit margin of -7973.33%.
Gross Margin94.31%
Operating Margin-8739.34%
Pretax Margin-7973.33%
Net Profit Margin-7973.33%
EBITDA Margin-7952.31%
EBIT Margin-7973.33%
Analyst Forecast
The average price target for Dianthus Therapeutics is $130.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$130.63
Price Target Upside40.07% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast-79.52%
EPS Growth Forecast-43.40%